Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Taysha Gene Therapies' Other Non-Current Assets changed 0.0% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.2 million for FY2024, which is 1726.92% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Other Non-Current Assets of $2.6 million as of Q3 2025, which was down 0.0% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other Non-Current Assets ranged from a high of $2.6 million in Q1 2022 and a low of $2.2 million during Q4 2024
  • Over the past 4 years, Taysha Gene Therapies' median Other Non-Current Assets value was $2.6 million (recorded in 2023), while the average stood at $2.6 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first changed by 0.0% in 2023, then crashed by 1726.92% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Other Non-Current Assets stood at $2.6 million in 2022, then fell by 1.4% to $2.6 million in 2023, then fell by 17.27% to $2.2 million in 2024, then grew by 20.87% to $2.6 million in 2025.
  • Its Other Non-Current Assets stands at $2.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.6 million for Q1 2025.